Summary:
A number of studies have suggested that prior chemotherapy correlates negatively with the efficiency of hematopoietic stem cell mobilization. However, little data exist with regard to the relative effects of the specific chemotherapeutic drug classes. We retrospectively reviewed the records of 201 consecutive patients with nonmyeloid malignancies undergoing CD34+ cell mobilization with chemotherapy+granulocyte colony-stimulating factor (G-CSF). The number of prior chemotherapy courses correlated negatively with the peripheral CD34+ cell concentration (pCD34) on the first day of collection (P<0.001). No significant correlation was found for age, gender, tumor primary, mobilization chemotherapy regimen, disease status, marrow involvement, prior radiation therapy, or dose and timing of G-CSF administration. When the number of courses of individual classes of chemotherapeutic agents was correlated with pCD34, only exposures to platinum compounds (P=0.001) and alkylating agents (P=0.01) were found to be independent negative predictive factors for pCD34. Within classes, DNA crosslinking agents and etoposide appeared possibly more damaging than DNA methylating agents and doxorubicin, respectively. None of the drug classes showed evidence of recovery. We conclude that exposure to chemotherapy, especially platinum compounds and alkylating agents, should be minimized prior to mobilization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17.
Chabannon C, Le Coroller AG, Faucher C et al. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 1995; 4: 171–179.
Koumakis G, Vassilomanolakis M, Hatzichristou H et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD, CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065–1072.
Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.
Keung YK, Cobos E, Dunn D et al. Determining factors for the outcome of peripheral blood progenitor cells harvests. J Clin Apheresis 1996; 11: 23–26.
Humpe A, Riggert J, Vehmeyer K et al. Comparison of CD34+ cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy. Transfusion 1997; 37: 1050–1057.
Olivieri A, Offidani M, Ciniero L et al. Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplant 1994; 14: 273–278.
Shepherd KM, Charles P, Sage RE et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25–32.
Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.
Imrie K, Stewart K, Crump RM et al. Blood stem cell collection: factors influencing the recovery of granulocyte–macrophage colony forming cells. Cell Transplant 1996; 5: 379–383.
McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma. Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228–233.
Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.
Morton J, Morton A, Bird R et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21–27.
Sutherland R, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213–226.
Ford CD, Chan K, Reilly WF, Petersen FB . An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003; 43: 622–625.
Ford CD, Greenwood J, Strupp A, Lehman CM . Change in CD34+ cell concentration during peripheral blood stem cell collection: effects on collection efficiency and efficacy. Transfusion 2002; 42: 904–911.
Narayanasami U, Kanteti R, Morelli J et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.
Weaver CH, Birch R, Greco L et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338–347.
Demirer T, Ayli M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468–474.
Andre M, Baudoux E, Bron D et al. Phase III randomized study comparing 5 or 10 g per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50–57.
Drake M, Ranaghan L, Morris TCM et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749.
Clark RE, Brammer CG . Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863.
Neben S, Hemman S, Montgomery M et al. Hematopoietic stem cell deficit of transplanted bone marow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156–162.
Molineux G, Xu C, Hendry J, Testa NG . A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide. Cancer Chemother Pharmacol 1986; 18: 11–16.
Adler SS, Kuznetshy RD . Effects of chemotherapeutic agents on hemopoietic stromal tissue: I. Effects of cyclophosphamide and bleomycin on hemopoiesis in subcutaneous femur implants. Exp Hematol 1984; 12: 153–161.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ford, C., Green, W., Warenski, S. et al. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 33, 901–905 (2004). https://doi.org/10.1038/sj.bmt.1704455
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704455
Keywords
This article is cited by
-
Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma
Annals of Hematology (2022)
-
Nociceptive nerves regulate haematopoietic stem cell mobilization
Nature (2021)
-
Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group
Annals of Hematology (2016)
-
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study
Annals of Hematology (2016)
-
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis
Bone Marrow Transplantation (2015)